AstraZeneca ramps up oncology pipeline PharmaTimes The Novartis mTOR inhibitor everolimus is a prime example. Currently this has been combined with the aromatase inhibitor letrozole, but Nunn sees scope for a Faslodex combination: “There is already some Phase II data in the public domain, so that is an ... |
